Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lorcaserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C known ✓ | P28335 | 20/20 | 0.94 |
| ▸ | HTR2A | P28223 | 20/20 | 0.94 |
| ▸ | HTR2B | P41595 | 18/20 | 0.94 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.94 |
| ▸ | HTR1A | P08908 | 1/20 | 0.94 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.94 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.94 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.94 |
| ▸ | CNR1 | P21554 | 1/20 | 0.94 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.94 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.94 |
| ▸ | HRH1 | P35367 | 1/20 | 0.94 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.94 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lorcaserin SCHEMBL30418169 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL19179796 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL5318608 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL173223 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL3757691 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL5318606 | 1.00 | HTR2A (0.94) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174044 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL174046 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL1954700 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A | |
| Lorcaserin SCHEMBL173899 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR2BADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170239263-A1 | METHOD OF WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | claimed |
| WO-2016069875-A1 | COMPOSITIONS AND METHODS FOR CEASING TOBACCO SMOKING | ARENA PHARMACEUTICALS, INC. (US) | 2016-05-06 | — | — | WO | claimed |
| US-20160009654-A1 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE | ARENA PHARMACEUTICALS, INC. | 2016-01-14 | — | — | US | claimed |
| US-20150297610-A1 | METHOD OF WEIGHT MANAGEMENT | ARENA PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | US | claimed |
| EP-2327698-B1 | Process for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate | ARENA PHARM INC (US) | 2015-08-05 | — | — | EP | claimed |
| US-8980881-B2 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride | ARENA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | claimed |
| US-20150038701-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | claimed |
| US-8802845-B2 | Processes for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine and intermediates related thereto | Arena Phamaceuticals, Inc. (US) | 2014-08-12 | — | — | US | claimed |
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. | 2014-05-29 | — | — | US | claimed |
| US-8697686-B2 | Crystalline forms of (R)-8-chloro-1-methyl-2,3,4,5-thtrahydro-1H-3-benzazepine hydrochloride | ARENA PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-8168624-B2 | lorcaserin hydrochloride; obesity | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | claimed |
| US-8168782-B2 | synthesis of lorcaserin | ARENA PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | claimed |
| WO-2012030951-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| EP-2327698-A1 | Process for preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate | Arena Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | claimed |
| EP-2149562-A1 | method of preparing (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride hemihydrate | Arena Pharmaceuticals, Inc. (US) | 2010-02-03 | — | — | EP | claimed |
| US-20100004223-A1 | Crystalline Forms Of (R)-8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine Hydrochloride | Arena Phamaceuticals, Inc. (CA) | 2010-01-07 | — | — | US | claimed |
| EP-1838677-B1 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE | ARENA PHARM INC (US) | 2009-09-09 | — | — | EP | claimed |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | ARENA PHARMACEUTICALS, INC. | 2009-06-04 | — | — | US | claimed |
| EP-2001852-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007120517-A2 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038701-A1 | PROCESSES FOR THE PREPARATION OF 8-CHLORO-1-METHYL-2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE AND INTERMEDIATES RELATED THERETO | HTR2C, HTR3C, HTR1A | HTR2C 1/4885HTR2A 12/4885HTR2B 17/4885 |
| US-20090143576-A1 | Processes for the Preparation of 8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine and Intermediates Related Thereto | HTR2C, HTR3C, HTR1A | HTR2C 1/4885HTR2A 12/4885HTR2B 17/4885 |
| US-20140148442-A1 | FAST-DISSOLVE DOSAGE FORMS OF 5-HT2C AGONISTS | HTR2C, HTR2A, HTR1A | HTR2C 1/4885HTR2A 2/4885HTR2B 11/4885 |
| US-20170239263-A1 | METHOD OF WEIGHT MANAGEMENT | GCG, CEL, GCKR | HTR2C 150/4885HTR2A 345/4885HTR2B 312/4885 |
| US-20100004223-A1 | Crystalline Forms Of (R)-8-Chloro-1-Methyl-2,3,4,5-Tetrahydro-1H-3-Benzazepine Hydrochloride | GRIN2C, HTR3C, GRIN3A | HTR2C 8/4885HTR2A 61/4885HTR2B 104/4885 |
| US-20150297610-A1 | METHOD OF WEIGHT MANAGEMENT | GCG, CEL, GCKR | HTR2C 150/4885HTR2A 345/4885HTR2B 312/4885 |
| US-20160009654-A1 | CRYSTALLINE FORMS OF (R)-8-CHLORO-1-METHYL- 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINE HYDROCHLORIDE | GRIN2C, HTR3C, GRIN2D | HTR2C 5/4885HTR2A 40/4885HTR2B 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.